This post was originally published on this site
The U.S. FDA was meeting to consider the need for booster shots of the Moderna (NASDAQ:MRNA) Inc. vaccine.
Israel, which has been closely monitoring vaccines in its population, said in a slide presentation that administering a booster dose led to greater protection against confirmed infection in those aged 16 and above.
